Cargando…

Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma

Natural killer (NK) cells are innate lymphocytes with a strong antitumor ability. In tumor patients, such as multiple myeloma (MM) patients, an elevated number of NK cells after stem cell transplantation (SCT) has been reported to be correlated with a higher overall survival rate. With the aim of im...

Descripción completa

Detalles Bibliográficos
Autores principales: Tognarelli, Sara, Wirsching, Sebastian, von Metzler, Ivana, Rais, Bushra, Jacobs, Benedikt, Serve, Hubert, Bader, Peter, Ullrich, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277768/
https://www.ncbi.nlm.nih.gov/pubmed/30542346
http://dx.doi.org/10.3389/fimmu.2018.02743
_version_ 1783378226040537088
author Tognarelli, Sara
Wirsching, Sebastian
von Metzler, Ivana
Rais, Bushra
Jacobs, Benedikt
Serve, Hubert
Bader, Peter
Ullrich, Evelyn
author_facet Tognarelli, Sara
Wirsching, Sebastian
von Metzler, Ivana
Rais, Bushra
Jacobs, Benedikt
Serve, Hubert
Bader, Peter
Ullrich, Evelyn
author_sort Tognarelli, Sara
collection PubMed
description Natural killer (NK) cells are innate lymphocytes with a strong antitumor ability. In tumor patients, such as multiple myeloma (MM) patients, an elevated number of NK cells after stem cell transplantation (SCT) has been reported to be correlated with a higher overall survival rate. With the aim of improving NK cell use for adoptive cell therapy, we also addressed the cytotoxicity of patient-derived, cytokine-stimulated NK cells against MM cells at specific time points: at diagnosis and before and after autologous stem cell transplantation. Remarkably, after cytokine stimulation, the patients' NK cells did not significantly differ from those of healthy donors. In a small cohort of MM patients, we were able to isolate autologous tumor cells, and we could demonstrate that IL-2/15 stimulated autologous NK cells were able to significantly improve their killing capacity of autologous tumor cells. With the aim to further improve the NK cell killing capacity against MM cells, we investigated the potential use of NK specific check point inhibitors with focus on NKG2A because this inhibitory NK cell receptor was upregulated following ex vivo cytokine stimulation and MM cells showed HLA-E expression that could even be increased by exposure to IFN-γ. Importantly, blocking of NKG2A resulted in a significant increase in the NK cell-mediated lysis of different MM target cells. Finally, these results let suggest that combining cytokine induced NK cell activation and the specific check point inhibition of the NKG2A-mediated pathways can be an effective strategy to optimize NK cell therapeutic approaches for treatment of multiple myeloma.
format Online
Article
Text
id pubmed-6277768
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62777682018-12-12 Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma Tognarelli, Sara Wirsching, Sebastian von Metzler, Ivana Rais, Bushra Jacobs, Benedikt Serve, Hubert Bader, Peter Ullrich, Evelyn Front Immunol Immunology Natural killer (NK) cells are innate lymphocytes with a strong antitumor ability. In tumor patients, such as multiple myeloma (MM) patients, an elevated number of NK cells after stem cell transplantation (SCT) has been reported to be correlated with a higher overall survival rate. With the aim of improving NK cell use for adoptive cell therapy, we also addressed the cytotoxicity of patient-derived, cytokine-stimulated NK cells against MM cells at specific time points: at diagnosis and before and after autologous stem cell transplantation. Remarkably, after cytokine stimulation, the patients' NK cells did not significantly differ from those of healthy donors. In a small cohort of MM patients, we were able to isolate autologous tumor cells, and we could demonstrate that IL-2/15 stimulated autologous NK cells were able to significantly improve their killing capacity of autologous tumor cells. With the aim to further improve the NK cell killing capacity against MM cells, we investigated the potential use of NK specific check point inhibitors with focus on NKG2A because this inhibitory NK cell receptor was upregulated following ex vivo cytokine stimulation and MM cells showed HLA-E expression that could even be increased by exposure to IFN-γ. Importantly, blocking of NKG2A resulted in a significant increase in the NK cell-mediated lysis of different MM target cells. Finally, these results let suggest that combining cytokine induced NK cell activation and the specific check point inhibition of the NKG2A-mediated pathways can be an effective strategy to optimize NK cell therapeutic approaches for treatment of multiple myeloma. Frontiers Media S.A. 2018-11-27 /pmc/articles/PMC6277768/ /pubmed/30542346 http://dx.doi.org/10.3389/fimmu.2018.02743 Text en Copyright © 2018 Tognarelli, Wirsching, von Metzler, Rais, Jacobs, Serve, Bader and Ullrich. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tognarelli, Sara
Wirsching, Sebastian
von Metzler, Ivana
Rais, Bushra
Jacobs, Benedikt
Serve, Hubert
Bader, Peter
Ullrich, Evelyn
Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
title Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
title_full Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
title_fullStr Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
title_full_unstemmed Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
title_short Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma
title_sort enhancing the activation and releasing the brakes: a double hit strategy to improve nk cell cytotoxicity against multiple myeloma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277768/
https://www.ncbi.nlm.nih.gov/pubmed/30542346
http://dx.doi.org/10.3389/fimmu.2018.02743
work_keys_str_mv AT tognarellisara enhancingtheactivationandreleasingthebrakesadoublehitstrategytoimprovenkcellcytotoxicityagainstmultiplemyeloma
AT wirschingsebastian enhancingtheactivationandreleasingthebrakesadoublehitstrategytoimprovenkcellcytotoxicityagainstmultiplemyeloma
AT vonmetzlerivana enhancingtheactivationandreleasingthebrakesadoublehitstrategytoimprovenkcellcytotoxicityagainstmultiplemyeloma
AT raisbushra enhancingtheactivationandreleasingthebrakesadoublehitstrategytoimprovenkcellcytotoxicityagainstmultiplemyeloma
AT jacobsbenedikt enhancingtheactivationandreleasingthebrakesadoublehitstrategytoimprovenkcellcytotoxicityagainstmultiplemyeloma
AT servehubert enhancingtheactivationandreleasingthebrakesadoublehitstrategytoimprovenkcellcytotoxicityagainstmultiplemyeloma
AT baderpeter enhancingtheactivationandreleasingthebrakesadoublehitstrategytoimprovenkcellcytotoxicityagainstmultiplemyeloma
AT ullrichevelyn enhancingtheactivationandreleasingthebrakesadoublehitstrategytoimprovenkcellcytotoxicityagainstmultiplemyeloma